Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment

Urology

Volumn 49, Issue 4, 1997, Pages 541-547

  Ick, Kurt ^a   Schultz, Michael ^a   Stout, Paul ^a   Fan, Kang ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; PROTEIN P53;

ARTICLE; BLADDER BIOPSY; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BLADDER EPITHELIUM; CANCER GROWTH; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0030894347     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00624-3     Document Type: Article

References (30)

1. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pla, grades 1 and 1); the importance of recurrence pattern following initial resection. J Urol. 135:1986;920-922.
2. Gilbert HA, Logan JL, Lagan AR, Gilbert HA, Logan JL, Kagan AR, Friedman HA, Cove JK, Fox M, Muldoon TM, et al. The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. J Urol. 119:1978;488-492.
3. Althausen AF, Prout GR Jr, Dal JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 116:1976;575-580.
4. Lulzeyet W, Rubben H, Dalun H. Prognostic parameters in superficial bladder cancer an analysis of 315 cases. J Urol. 127:1987;250-252.
5. Prout GR Jr, Griffin PP, Shipley WU. Bladder carcinoma as systemic disease. Cancer. 43:1979;2532-2539.
6. el-Dairy WS, Harper JW, O'Conner PM, Veleulesu VE, Canman CE, Jackman J, Pretenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
7. Givol I, Givol D, Bulong S, Resnu J, Iserfery I, Hughes SH. Overexpression of human p21 waf1/cip1 arrests the growth of chicken embryo fibroblasts transformed by individual oncogenes. Oncogene. 11:1995;2609-2618.
8. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:1994;3391-3395.
9. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, Jackman J, O'Connor PM, Anderson CW, Appella E, et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem. 270:1995;29386-29391.
10. Lane DP. p53, guardian of the genome (News & Views). Nature. 238:1992;15.
11. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell. 57:1989;1083-1093.
12. Mercer WE, Avignolo C, Baserga R. Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol. 4:1984;276-281.
13. Sturzbecher HW, Chumakov P, Welch WJ, Jenkins JR. Mutant p53 proteins bind hsp72/73 cellular heat shock-related proteins in SV-40 transformed monkey cells. Oncogene. 1:1987;201-211.
14. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature. 362:1993;857-860.
15. Finlay CA, Hinds PW, Tan T, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half-life. Mol Cell Biol. 8:1988;531-539.
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 253:1991;49-53.
17. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature. 342:1989;705-708.
18. Fan K, Dao DD, Schutz M, Fink LM. Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma. Diagn Mol Pathol. 3:1994;265-270.
19. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51:1991;4716-4720.
20. Sidransky D, Von Eschenbach A, Tsai YC, Jones PA, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 252:1991;706-709.
21. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer. 56:1994;347-353.
22. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang Z, Sheinfeld J, Fair W, Herr H, Reuter VE. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 152:1994;388-392.
23. Spruck CH III, Ohnesit PF, Gonzales-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54:1994;784-788.
24. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 143:1993;1389-1397.
25. Kusser WC, Miao X, Glickman BW, Friedland JM, Rothman N, Hemstreet GP, Mellot J, Swan DC, Schulte PA, Hayes RB. p53 mutations in human bladder cancer. Environ Mol Mutagen. 24:1994;156-160.
26. Sarkis AS, Dalbagni G, Gordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 85:1993;53-59.
27. Hruban RH, van der Riet P, Erozan YS, Sidransky D. Brief report: molecular biology and the early detection of carcinoma of the bladder: the case of Hubert H. Humphrey. N Engl J Med. 330:1994;1276-1278.
28. Offner FA, Schafer G, Hittmair A, Ofner D, Grunewald K, Weyrer K, Mattern D, Eberle J, Mikuz G, Feichtinger HI. Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder (review). Verh Dtsch Ges Pathol. 77:1993;241-246.
29. Schmitz-Drager BJ, van Roeyen CR, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bultel H, Makri D, Ebert T, Ackermann R. p53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol. 12:1994;79-83.
30. Vet JA, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FM, Schalken JA. Comparison of p53 protein overexpression with p53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest. 73:1995;837-843.